Beam Therapeutics Inc. announced on Tuesday that the United Kingdom's Medicines and Healthcare Products Regulatory Agency has approved the company's Clinical Trial Authorization (CTA) application for BEAM-302. This approval pertains to the treatment of patients suffering from Alpha-1 Antitrypsin Deficiency (AATD).
AATD is a genetic condition passed through inheritance, it can lead to severe lung and liver diseases. Beam Therapeutics also disclosed its plans to commence a Phase 1/2 study of BEAM-302. This study, targeted at patients with AATD-linked lung diseases, is set to kick off in the first half of 2024.
